Back to News
investment

Remedy Entertainment Oyj (RMDEF) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Remedy reported Q4 2025 revenue of €17 million, nearing record levels, with EBITDA at €3.9 million and EBIT turning positive at €0.7 million, despite slightly negative cash flow. Leadership changes included Markus Mäki assuming interim CEO duties and Henri Österlund becoming Chairman of the Board, marking a strategic shift in executive oversight. The company launched a 2025 employee stock option plan and initiated a share repurchase program for 50,000 shares to optimize capital structure and align incentives. Full-year 2025 results highlighted growth, though specific annual figures weren’t detailed in the Q4 transcript, emphasizing the quarter’s strong performance as a key takeaway. Outlook for 2026 was teased but not elaborated, with the focus remaining on operational stability and financial discipline amid leadership transitions.
AI Audio Summary
0:00 / 0:00
Click to play
f7e9219d-7515-46fb-86c9-f4778fc4627f.jpeg
Quantum News · Media Library

SA Transcripts158.42K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Remedy Entertainment Oyj (RMDEF) Q4 2025 Earnings Call February 10, 2026 5:00 AM EST Company Participants Aapo Kilpinen - Manager of Investor RelationsMarkus Maki - Interim CEO, Chief Product Officer & DirectorSanttu Kallionpaa - Chief Financial Officer Presentation Aapo KilpinenManager of Investor Relations Ladies and gentlemen, dear Remedy investors, welcome to the Webcast for Remedy's Full year Results of 2025. My name is Aapo Kilpinen from Remedy's Investor Relations. Joining with me today are Remedy's Interim CEO, Markus Maki; and Remedy's CFO, Santtu Kallionpaa. Markus will guide us through the quarter and the full year, and then Santtu will dive deeper into the financials. We'll then look at the outlook for 2026 before moving to the Q&A session at the end of the webcast. [Operator Instructions] But without further ado, Markus, please, how did the quarter go? Markus MakiInterim CEO, Chief Product Officer & Director Well, welcome, everybody, on -- my behalf as well. It's an end of an interesting year for Remedy, so let's look back at what happened. So starting with Q4, the financial highlights. Our revenue was EUR 17 million, large growth. It was almost on the record level for us, but not quite a record quarter, but very close to that. EBITDA, EUR 3.9 million and EBIT was EUR 0.0 million (sic) [ EUR 0.7 million ] positive. Cash flow was a bit negative for the comparison period. One of the major events that happened during Q4, we, of course, had the change of the CEO and the Chairman of the Board. So I took the role of the Interim CEO and Henri Osterlund took the role of Chairman of the Board. We had -- we decided on a new option plan for our staff for 2025. And we also had a repurchase program for 50,000 of our own shares to optimize

Read Original

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.